As part of Takeda’s commitment to keeping investors well informed about our business activities and performance, and to enhance how we communicate with retail investors, we recently participated in a two-day online retail investor fair hosted by Nikkei Group.
In a virtual presentation, Masato Iwasaki, Representative Director, Japan General Affairs, described Takeda’s transformation into a global R&D-based biopharmaceutical company, with an international presence and an R&D partnership and investment strategy that’s in step with the evolution of the pharmaceutical market. Throughout this transformation, Takeda has remained true to its founding principle of sanpo yoshi, a business principle that means good for the seller (urite yoshi), good for the buyer (kaite yoshi) and good for society (seken yoshi).
Today, sanpo yoshi can be seen in the imperatives of our corporate philosophy pillars of Patient, People and Planet, which are brought to life through Takeda’s Access to Medicines programs, our commitment to excellence in employee conditions, and our ambitious actions to prevent and mitigate the effects of climate change.
The investor fair attracted 22,000 visitors over the two days and provided an excellent opportunity to share Takeda’s heritage and growth story with existing and potential shareholders. We will continue to engage with retail investors to build a deeper understanding of the company—our leadership, values, and strategy. A video of the presentation (in Japanese) can be viewed here.